Many Canadians looking for advanced weight management options have heard about Zepbound. This medication has created buzz due to its strong results in clinical studies.
Zepbound contains tirzepatide, the same ingredient as in Mounjaro, but it’s branded specifically for weight loss. People often wonder about its status north of the border.
Health Canada reviews new drugs carefully for safety and effectiveness. Approvals can take time, but updates happen regularly.
What Is Zepbound?
Zepbound is a once-weekly injectable medication made by Eli Lilly. It helps adults manage chronic weight issues when combined with diet and exercise.
The active ingredient, tirzepatide, mimics two gut hormones: GLP-1 and GIP. This dual action reduces appetite and slows digestion.
It targets obesity or overweight with related conditions like high blood pressure or sleep apnea. Users often feel fuller faster and eat less overall.
Clinical trials showed impressive outcomes. Many participants lost significant weight over months of use.
Difference Between Zepbound and Mounjaro
Zepbound and Mounjaro both contain tirzepatide from Eli Lilly. The main difference lies in their approved uses.
Mounjaro treats type 2 diabetes and has been available in Canada since 2023. Doctors sometimes prescribe it off-label for weight loss.
Zepbound focuses directly on chronic weight management. It allows higher doses tailored for obesity treatment.
This separate branding helps with specific approvals and insurance. Both come in prefilled KwikPens for easy weekly injections.
Is Zepbound Approved in Canada?
Yes, Zepbound is approved in Canada.
Health Canada authorized Zepbound (tirzepatide) KwikPen on May 13, 2025. It became available in pharmacies starting July 9, 2025.
This approval makes it the first dual GIP/GLP-1 agonist specifically for obesity in Canada.
Approval Timeline
Health Canada reviewed data from SURMOUNT clinical trials. These studies included thousands of adults with obesity.
Submission led to authorization in spring 2025. Distribution followed shortly after. Eli Lilly announced availability nationwide in summer 2025.
Indication Details
Approved for adults with BMI 30 or higher (obesity). Also for BMI 27+ with weight-related conditions.
Used alongside reduced-calorie diet and increased activity. Not for type 1 diabetes or children.
How Zepbound Works
Zepbound activates receptors for GIP and GLP-1 hormones. These naturally regulate blood sugar and appetite.
The dual mechanism helps control hunger signals in the brain. It also improves insulin sensitivity and delays stomach emptying.
This leads to lower calorie intake and better energy use. Many users report steady weight reduction.
Results build over time with consistent use. Lifestyle changes enhance the effects.
Clinical Results and Effectiveness
Trials like SURMOUNT-1 showed average weight loss of up to 21% at highest doses. Participants lost around 48 pounds on average.
Compared to placebo, Zepbound users saw much greater reductions. Benefits included improved blood pressure and cholesterol.
Head-to-head studies suggest it may outperform single-agonist options. Individual results vary based on starting weight and adherence.
Long-term use supports weight maintenance. Stopping may lead to some regain without habits in place.
Side Effects and Safety
Common side effects are mostly gastrointestinal. These include nausea, diarrhea, and constipation.
They often lessen as the body adjusts. Starting low and increasing dose helps manage them.
Here’s a comparison with similar medications:
| Aspect | Zepbound (Tirzepatide) | Wegovy (Semaglutide) | Mounjaro (Tirzepatide for Diabetes) |
|---|---|---|---|
| Common Side Effects | Nausea, vomiting, diarrhea, constipation, abdominal pain | Nausea, diarrhea, vomiting, constipation | Similar to Zepbound; GI issues prominent |
| Frequency of GI Issues | Higher at start, improves over time | Common, dose-dependent | Comparable due to same ingredient |
| Serious Risks | Thyroid tumors (warning), pancreatitis, gallbladder issues | Thyroid tumors (warning), pancreatitis, retinopathy | Same as Zepbound |
| Other Notes | Injection site reactions, fatigue | Headache, low blood sugar with other meds | Hypoglycemia risk higher in diabetes use |
| Mitigation | Slow dose escalation, hydration | Eat smaller meals, start low | Monitor blood sugar if diabetic |
Rare serious risks include thyroid concerns. Discuss family history with your doctor.
Stay hydrated and eat fiber-rich foods. Report severe symptoms promptly.
Dosing and How to Use
Zepbound comes in single-dose KwikPens. Doses range from 2.5 mg to 15 mg. Start low to reduce side effects.
Inject under the skin weekly. Rotate sites like abdomen or thigh. No need to mix or measure. Missed doses can be taken soon after. Follow instructions carefully.
Cost and Coverage in Canada
Prices align with similar medications, often hundreds per month without coverage. Manufacturer programs like myZepbound help eligible patients.
Private insurance increasingly covers it for weight management. Public plans vary by province.
Check your policy for prior authorization needs. Appeals succeed with medical support. Savings cards reduce out-of-pocket costs. Pharmacies like Shoppers Drug Mart stock it.
Alternatives in Canada
While waiting earlier, many used Mounjaro off-label. Now Zepbound offers direct approval.
Other options include Wegovy (semaglutide) for weight loss. Saxenda is another injectable.
Oral meds and lifestyle programs exist. Consult providers for best fit. Compounded versions lack approval. Stick to branded for safety.
Getting Started with Zepbound
Talk to your doctor about eligibility. They assess BMI and health conditions. Get a prescription if suitable. Pharmacies fill it nationwide.
Online clinics offer consultations. Monitor progress regularly. Combine with diet and exercise for best results. Support groups help motivation.
Summary
Zepbound received Health Canada approval in May 2025 and launched in July, offering Canadians a powerful dual-action option for chronic weight management.
With tirzepatide as its active ingredient, it provides significant weight loss potential when paired with healthy habits. Availability has improved access, though costs and coverage vary. Always work with healthcare professionals to determine if it’s right for you, considering benefits, side effects, and alternatives.
FAQ
When was Zepbound approved in Canada?
Health Canada approved Zepbound on May 13, 2025. It became widely available in pharmacies starting July 9, 2025.
Is Zepbound the same as Mounjaro in Canada?
Both contain tirzepatide, but Mounjaro is approved for type 2 diabetes, while Zepbound is specifically for weight management with higher doses available.
How much weight can you lose with Zepbound?
Clinical trials showed average losses of 15-21% body weight over 72 weeks at higher doses, often around 48 pounds, depending on individual factors and lifestyle.
Does insurance cover Zepbound in Canada?
Many private plans cover it, often requiring prior authorization. Public coverage is limited and varies by province; manufacturer savings programs help reduce costs.
Dr. Hamza is a medical content reviewer with over 12+ years of experience in healthcare research and patient education. He specializes in evidence-based health information, medications, and chronic conditions. His reviews are grounded in trusted medical sources and current clinical guidelines to ensure accuracy, transparency, and reliability. Content reviewed by Dr. Hamza is intended for educational purposes and is not a substitute for professional medical advice.